Dr Reddy’s Laboratories has launched rivastigmine tartrate capsules (1.5 mg, 3 mg, 4.5 mg and 6 mg), a bioequivalent generic version of Exelon capsules in the US market on September 15, 2011 following the approval by the United States Food & Drug Administration (US FDA) of Dr Reddy’s ANDA for rivastigmine tartrate capsules.

The Exelon brand and generic rivastigmine tartrate had US sales of approximately $92.6 million for the most recent twelve months ending June 2011 according to IMS Health.

Dr Reddy’s rivastigmine tartrate capsules 1.5 mg, 3 mg, 4.5 mg and 6 mg strengths are available in 60 count bottles.

Dr Reddy’s Laboratories, an emerging global pharmaceutical company and fulfills the purpose of providing affordable and innovative medicines through three core businesses: pharmaceutical services and active ingredients, global generics and proprietary products.